Evidence map›Paper›PMID 40283161›Full record

ArticleLife (Basel, Switzerland)2025

A Combined Approach Using T2*-Weighted Dynamic Susceptibility Contrast MRI Perfusion Parameters and Radiomics to Differentiate Between Radionecrosis and Glioma Progression: A Proof-of-Concept Study.

José Pablo Martínez Barbero, Francisco Javier Pérez García, David López Cornejo, Marta García Cerezo, Paula María Jiménez Gutiérrez, Luis Balderas, Miguel Lastra, Antonio Arauzo-Azofra, José M Benítez, Antonio Jesús Láinez Ramos-Bossini

Abstract read
In one paragraph

Article in Life (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

José Pablo Martínez BarberoAdvanced Medical Imaging Group (TeCe22), Instituto de Investigación Biosanitaria de Granada (ibs.GRANADA), 18012 Granada, Spain.ORCID 0000-0003-4217-0633
Francisco Javier Pérez GarcíaAdvanced Medical Imaging Group (TeCe22), Instituto de Investigación Biosanitaria de Granada (ibs.GRANADA), 18012 Granada, Spain.
David López CornejoAdvanced Medical Imaging Group (TeCe22), Instituto de Investigación Biosanitaria de Granada (ibs.GRANADA), 18012 Granada, Spain.
Marta García CerezoAdvanced Medical Imaging Group (TeCe22), Instituto de Investigación Biosanitaria de Granada (ibs.GRANADA), 18012 Granada, Spain.
Paula María Jiménez GutiérrezAdvanced Medical Imaging Group (TeCe22), Instituto de Investigación Biosanitaria de Granada (ibs.GRANADA), 18012 Granada, Spain.
Luis BalderasAdvanced Medical Imaging Group (TeCe22), Instituto de Investigación Biosanitaria de Granada (ibs.GRANADA), 18012 Granada, Spain.ORCID 0000-0002-3845-8848
Miguel LastraAdvanced Medical Imaging Group (TeCe22), Instituto de Investigación Biosanitaria de Granada (ibs.GRANADA), 18012 Granada, Spain.
Antonio Arauzo-AzofraDepartment of Rural, Civil Engineering and Project Management, University of Córdoba, 14014 Córdoba, Spain.ORCID 0000-0002-2486-5792
José M BenítezAdvanced Medical Imaging Group (TeCe22), Instituto de Investigación Biosanitaria de Granada (ibs.GRANADA), 18012 Granada, Spain.ORCID 0000-0002-2346-0793
Antonio Jesús Láinez Ramos-BossiniAdvanced Medical Imaging Group (TeCe22), Instituto de Investigación Biosanitaria de Granada (ibs.GRANADA), 18012 Granada, Spain.ORCID 0000-0002-0663-2856

Funding

FEDER, EU PID2023-151336OB-I00MICIU/AIE/10.13039/501100011033 PID2020-118224RB-I00
6 · The paper itself

Abstract

Differentiating tumor progression from radionecrosis in patients with treated brain glioma represents a significant clinical challenge due to overlapping imaging features. This study aimed to develop and evaluate a machine learning model that integrates radiomics features and T2*-weighted Dynamic Susceptibility Contrast MRI perfusion (DSC MRI) parameters to improve diagnostic accuracy in distinguishing these entities. A retrospective cohort of 46 patients (25 with confirmed radionecrosis, 21 with glioma progression) was analyzed. From lesion segmentation on DSC MRI, 851 radiomics features were extracted using PyRadiomics, alongside seven perfusion parameters (e.g., relative cerebral blood volume, time to peak) obtained from time-intensity curves (TICs). These features were combined into a single dataset and 14 classification algorithms were evaluated with GroupKFold cross-validation (k = 4). The top-performing model was selected based on predictive area under the curve (AUC) yield. The Logistic Regression classifier achieved the highest performance, with an AUC of 0.88, followed by multilayer perceptron and AdaBoost with AUC values of 0.85 and 0.79, respectively. The precision values were 72%, 74%, and 78% for the three models, respectively, while the accuracy was 63%, 70%, and 71%. Key predictive variables included radiomics features like wavelet-HHH_firstorder_Mean and mean normalized TIC values. Our combined approach integrating radiomics and DSC MRI parameters shows strong potential for distinguishing radionecrosis from glioma progression. However, further validation with larger cohorts is essential to confirm the generalizability of this approach.

Indexed as

gliomamachine learningmagnetic resonance imagingperfusionradiomicsradionecrosistumor progression

Identifiers

PMID40283161
PMCPMC12028526

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.